Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P950029/S134

Reply SR; Reply DR; ALIZEA SR 1300; ALIZEA DR 1600; CELEA SR 1100; CELEA DR 1400

MicroPort CRM S.r.l. · Decision date Jul 23, 2025

FDA DECISIONP950029/S134

What did the FDA approve?

FDA records P950029/S134 as a supplement to PMA P950029, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Jul 23, 2025.

FDA approval order statement

Approval for the addition of Mylar spacers to our ALIZEA/CELEA pacemakers, allow hybrid tab replacements to occur at Microports Saluggia, Italy facility, and changes in manufacturing processes of other MicroPorts pacemaker, ICD, and CRT-D systems.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Cardiovascular
Decision date
Jul 23, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P950029/S134
Regulatory pathway
PMA supplement
Product code
DXY
Decision code
APPR
Decision date
Jul 23, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: implantable pacemaker Pulse-generator.

Product code
DXY
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P950029/S134 received

    Application receipt date recorded by FDA.

  2. P950029/S134 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P950029. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code DXY

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

MicroPort CRM S.r.l.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Via Crescentino S.N., Saluggia, 13040

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records